biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Saulamanca	12/11/2006 8:26:58 AM
	Read Replies (1) of 3661

NUVO down 80% premarket Nuvelo announces Phase 3 trials of Alfimeprase in patients w/acute peripheral arterial occlusion and catheter occlusion didn't meet primary endpoints (NUVO) 19.55 : Co and Bayer HealthCare (BAY) announce top-line data demonstrating that the Phase 3 clinical trial of alfimeprase in acute peripheral arterial occlusion, known as NAPA-2, did not meet its primary endpoint of avoidance of open vascular surgery within 30 days of treatment. The cos also announced that the Phase 3 trial in catheter occlusion, known as SONOMA-2, did not meet the endpoint of restoration of function at 15 minutes. These trials did not meet key secondary endpoints. In addition, the cos announced that they have temporarily suspended enrollment in the ongoing Phase 3 trials, NAPA-3 and SONOMA-3, until further analyses and discussions with outside experts and regulatory agencies are completed. These data will be submitted for presentation at the next appropriate medical meetings.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next